Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Gut microbiota in mice with damp-heat diarrhea-predominant irritable bowel syndrome

PROVIDER: PRJNA1119274 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29261025_1.fastq.gz	Fastqsanger.gz
	SRR29261025_2.fastq.gz	Fastqsanger.gz
	SRR29261026_1.fastq.gz	Fastqsanger.gz
	SRR29261026_2.fastq.gz	Fastqsanger.gz
	SRR29261027_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 80

Similar Datasets

Expression data from healthy volunteers and IBS patients

Project description:Micro-inflammation and gut dysfunction are features of diarrhea-irritable bowel syndrome (d-IBS) patients, although the underlying interacting molecular mechanisms remain mostly unknown. Therefore, we aimed to identify critical networks and signaling pathways active in chronic diarrhea-associated inflammation. Keywords: Comparison of gene expression

2009-02-14 | GSE14841 | GEO

Colonic proteome signature in immunoproteasome-deficient stressed mice and its relevance for irritable bowel syndrome

Project description:A role for immunoproteasome in the regulation of intestinal permeability has been previously suggested both in mice during water avoidance stress (WAS) and in patients with irritable bowel syndrome (IBS). We thus aimed (i) to evaluate the colonic proteome in wild-type (wt) and β2i immunoproteasome subunit knock-out (β2i-/-) mice during WAS and (ii) to investigate the colonic expression of 49 ubiquitinated-proteins in diarrhea-predominant IBS patients (IBS-D).

2018-12-05 | PXD011199 | Pride

Transcription profiling of human healthy volunteers and IBS patients

2009-02-21 | E-GEOD-14841 | biostudies-arrayexpress

Application of gut microbiota in dynamic evaluation of TCM syndromes and canceration in patient with colorectal tumor

Project description:Interventions: Colorectal adenoma (excessive syndrome: intestinal damp-heat syndrome) group:None;Colorectal adenoma (deficiency syndrome: spleen and stomach deficiency syndrome) group:None;Colorectal cancer (excessive syndrome: damp-heat accumulation syndrome) group:None;Colorectal cancer (deficiency syndrome: spleen deficiency and qi stagnation syndrome) group:None;Healthy control group:None Primary outcome(s): Gut microbiota Study Design: Factorial

| 2741054 | ecrin-mdr-crc

Colonic Gene expression in mice colonized with human gut microbiota from healthy and IBS patients

Project description:Irritable Bowel Syndrome (IBS) is a disorder of the gut-brain axis, characterized by altered gut function and frequent psychiatric co-morbidity. Although altered intestinal microbiome profiles have been documented, their relevance to the clinical expression of IBS is unknown. To evaluate a functional role of the microbiota, we colonized germ-free mice with fecal microbiota from healthy controls or IBS patients with accompanying anxiety, and monitored gut function and behavior. Mouse microbiota profiles clustered according to their human donors. Despite having taxonomically similar composition as controls, mice with IBS microbiota had distinct serum metabolomic profiles related to neuro- and immunomodulation. Mice with IBS, but not control microbiota, exhibited faster gastrointestinal transit, intestinal barrier dysfunction, innate immune activation and anxiety-like behavior. These results support the notion that the microbiota contributes to both intestinal and behavioral manifestations of IBS and rationalize the use of microbiota-directed therapies in ameliorating IBS.

2017-03-02 | GSE61841 | GEO

Transcription profiling of human IBS patients before and after treatment

Project description:Increased numbers of mast cells and their products have been linked to symptom onset and severity in patients with chronic diarrhea and abdominal pain. Although mast-cell inhibition ameliorates clinical manifestations and reduces mucosal inflammation, underlying molecular mechanisms remain unknown. Experiment Overall Design: Diarrhea-irritable bowel syndrome (d-IBS) patients were studied at baseline, or 6 months after natural evolution (control) or oral cromoglycate treatment. Jejunal biopsies were subjected to chip analysis (Affymetrix Human Genome U133 Plus 2.0 GeneChips).

2009-02-21 | E-GEOD-14842 | biostudies-arrayexpress

rat gut metagenome

Project description:Curcumin Attenuates Constipation-Predominant Irritable Bowel Syndrome by Regulating Gut Microbiota and Neurotransmitters

| PRJNA1003150 | ENA

Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome (16S)

Project description:Changes in microbiome composition have been associated with a wide array of human diseases, turning the human microbiota into an attractive target for therapeutic intervention. Yet clinical translation of these findings requires the establishment of causative connections between specific microbial taxa and their functional impact on host tissues. Here, we infused gut organ cultures with longitudinal microbiota samples collected from therapy-naïve irritable bowel syndrome (IBS) patients under low-FODMAP (fermentable Oligo-, Di-, Mono-saccharides and Polyols) diet. We show that post-diet microbiota regulates intestinal expression of inflammatory and neuro-muscular gene-sets. Specifically, we identify Bifidobacterium adolescentis as a diet-sensitive pathobiont that alters tight junction integrity and disrupts gut barrier functions. Collectively, we present a unique pathway discovery approach for mechanistic dissection and identification of functional diet-host-microbiota modules. Our data support the hypothesis that the gut microbiota mediates the beneficial effects of low-FODMAP diet and reinforce the potential feasibility of microbiome based-therapies in IBS.

2022-10-14 | GSE215047 | GEO

Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome (RNA-Seq II)

2022-10-14 | GSE215049 | GEO

Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome (RNA-Seq I)

2022-10-14 | GSE215048 | GEO